Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
uniQure N.V. - Ordinary Shares
(NQ:
QURE
)
16.65
+0.30 (+1.83%)
Streaming Delayed Price
Updated: 10:16 AM EDT, Apr 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about uniQure N.V. - Ordinary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
uniQure Stock Tumbled 56% Today: What’s The FDA Angle?
↗
November 03, 2025
Via
Stocktwits
Gapping stocks in Monday's session
↗
November 03, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
November 03, 2025
From
The DJS Law Group
Via
Business Wire
Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings
↗
November 03, 2025
Via
Benzinga
Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy
↗
November 03, 2025
An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.
Via
Investor's Business Daily
Discover the top movers in Monday's pre-market session.
↗
November 03, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
November 03, 2025
Via
Benzinga
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
November 03, 2025
From
uniQure Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
October 30, 2025
Via
Benzinga
Breakout Momentum Plays You Need to Know About
↗
October 23, 2025
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.
Via
MarketBeat
Why Is Protalix BioTherapeutics Stock Falling On Friday?
↗
October 17, 2025
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
Via
Benzinga
Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet
↗
October 06, 2025
Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises selling some Dillard's (DDS).
Via
Benzinga
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop
↗
October 03, 2025
Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come.
Via
MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
↗
October 01, 2025
Via
Benzinga
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
September 29, 2025
From
uniQure Inc.
Via
GlobeNewswire
Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide
↗
September 27, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
uniQure Announces Pricing of Upsized $300 Million Public Offering
September 25, 2025
From
uniQure Inc.
Via
GlobeNewswire
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
↗
September 25, 2025
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease...
Via
Benzinga
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
↗
September 25, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
uniQure Stock Jumps On Positive News, But Risks Remain
↗
September 25, 2025
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in...
Via
Benzinga
Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Funding
↗
September 25, 2025
After weeks of record highs fueled by AI optimism, U.S. stocks cooled for a second straight day. Oracle’s massive debt raise and divergent moves in chipmakers set the tone, while housing and lithium...
Via
Chartmill
Topics
Artificial Intelligence
Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today
↗
September 24, 2025
U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85.
Via
Benzinga
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’
↗
September 24, 2025
UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.
Via
Stocktwits
uniQure Announces $200 Million Proposed Public Offering
September 24, 2025
From
uniQure Inc.
Via
GlobeNewswire
Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall
↗
September 24, 2025
Via
Benzinga
What's Going On With UniQure Stock Wednesday?
↗
September 24, 2025
UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease.
Via
Benzinga
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today
↗
September 24, 2025
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
September 24, 2025
Via
Benzinga
A Cure For Huntington's Disease? UniQure Launches More Than 240%.
↗
September 24, 2025
The company's gene therapy slowed disease progression by 75% over three years.
Via
Investor's Business Daily
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
↗
September 24, 2025
UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
